SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is facing significant selling pressure as investors scrutinize the high costs of AI infrastructure investments and their impact on near-term cash flows. While some community members are concerned by the stock's recent performance compared to other tech sectors, others are actively viewing these price levels as a long-term opportunity, emphasizing the company's strong fundamentals and ongoing data center expansion.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending ahead of upcoming earnings as investors react to a fresh analyst upgrade from Stifel, which highlighted the company's critical role in the physical AI infrastructure market. The community is actively debating the company's transition away from legacy roots, with long-term shareholders expressing conviction in QNX technology while navigating volatility and ongoing concerns about potential manipulation of the share price.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is surging after delivering record-shattering earnings and revenue, largely driven by unrelenting demand for AI-focused memory and lucrative, long-term customer contracts. The market is reacting with extreme bullishness, as investors and community members discuss a structural 'supercycle' for memory that potentially renders traditional cyclical downturns irrelevant.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is gaining momentum as investors bet on the company's dual obesity drug pipeline and the potential for a transformative partnership or acquisition. The community is actively discussing ongoing institutional buying, high short interest, and the significance of upcoming maintenance trial data in validating the drug's long-term commercial value.

Alibaba Group Holding Ltd. engages in providing technology infrastructure and marketing reach. It operates through the following business segments: China Commerce, International Commerce, Local Consumer Services, Cainiao, Cloud, Digital Media and Entertainment, and Innovation Initiatives and Others segments. The Core Commerce segment consists of platforms operating in retail and wholesale. The China Commerce segment includes China commerce retail and wholesale businesses. The International Commerce segment focuses on international commerce retail and wholesale businesses. The Local Consumer Services segment is involved in To-Home businesses, which include Ele.me, local services and delivery platform, and Taoxianda, and To-Destination segment businesses which include Amap, the provider of mobile digital map, navigation and real-time traffic information, and restaurant and local services guide platform. The Cainiao segment has Cainiao Network and offers domestic and international one-stop-shop logistics services and supply chain management solution. The Cloud segment includes Alibaba Cloud and DingTalk. The company was founded by Chung Tsai and Yun Ma on June 28, 1999 and is headquartered in Hangzhou, China.

Alibaba Group Holding Ltd - ADR

Alibaba Group Holding Ltd

Alibaba is trending amidst a sharp price decline as the community debates whether the stock represents a long-term value opportunity or a persistent "value trap" amid geopolitical pressures, including accusations of illicit AI model access. Investors are actively discussing the stock's failure to rebound, with many expressing frustration over repeated overnight selling and a lack of clear catalysts to reverse the ongoing downtrend.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Biocryst Pharmaceuticals is seeing a surge in investor interest and volume driven by ongoing speculation regarding a potential buyout and excitement over the expansion of its HAE clinical portfolio. Community discourse is heavily focused on the stock's significant options activity and the debate over whether the current momentum is a genuine breakout or another instance of institutional manipulation.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is facing a significant market reaction following an aggressive shift toward AI data center infrastructure, headlined by a major acquisition of AI software startup Modular and strategic collaborative deals with hyperscalers like Microsoft and Meta. While the community is actively debating the company's long-term pivot away from handset dependency and its ambitious revenue growth targets, the stock price has experienced sharp volatility as investors weigh these high-growth potential catalysts against broader semiconductor sector fluctuations.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is gaining significant momentum as investors anticipate the final Phase 3 data from the REGAL trial, with the community closely tracking the 80th event milestone as a primary catalyst. Discussion is heavily focused on the stock's elevated short interest and rising borrow costs, fueling widespread speculation about a potential short squeeze amid ongoing institutional positioning for a major clinical readout.

Take-Two Interactive Software, Inc. engages in the development, publishing, and marketing of interactive software games. Its products are designed for console systems, handheld gaming systems, and personal computers, including smart phones and tablets, and are delivered through physical retail, digital download, online platforms, and cloud streaming services. The company was founded by Ryan A. Brant in 1993 and is headquartered in New York, NY.

Take-Two Interactive Software, Inc.

Take-Two Interactive is experiencing elevated volatility and intense social media discussion as traders monitor its upcoming quarterly results for any signals regarding the highly anticipated Grand Theft Auto VI, particularly given the community's vocal debates over the shift to digital-only releases and its impact on long-term profit margins. The community is focused on the tension between strong institutional sentiment toward the game's revenue potential and skepticism from traders about potential development delays or underwhelming guidance.

Absci Corp. is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. It partners with pharma and biotech innovators to create the next generation of protein-based drugs. The company was founded by Sean McClain in 2011 and is headquartered in Vancouver, WA.

Absci Corp

Absci Corp is surging following positive clinical trial data for its hair loss drug, ABS-201, coupled with a major equity raise backed by Eli Lilly and other institutional investors. The community is actively discussing the stock's significant momentum as a high-risk, high-reward play, with traders debating whether this AI-driven biotech breakout is a sustainable shift or a volatility-fueled liquidity event.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Intellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy in 2026?

Key PointsIntellia Therapeutics is leveraging its strategic partnership with Regeneron to advance a deep pipeline of CRISPR-based gene editing therapies...

This Stock Is Up 58% This Year. Is It too Late to Buy?

Key PointsOne of Intellia Therapeutics' leading candidates recently aced a phase 3 study...

NTLA Posts Strong Additional Phase III Data From HAE Study, Stock Up

Intellia jumps after additional phase III HAELO data showed lonvo-z cut on-demand-treated attacks by 89% and moderate-to-severe episodes by 91%.

Strength Seen in Intellia Therapeutics (NTLA): Can Its 23.2% Jump Turn into More Strength?

Intellia Therapeutics (NTLA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Nasdaq, S&P 500 Futures Cheer Iran Breakthrough, Crude Slides: Why SPCX, NVDA, RKLB, ASTS, RCAT, NTLA Are Keeping Traders Hooked

Equity

Despite the rebound in futures, Stocktwits data showed retail sentiment has moved to ‘bearish’ on SPY and QQQ.

Why Is NTLA Stock Jumping 5% Premarket Today?

Intellia unveiled additional Phase 3 data for its CRISPR-based HAE treatment, Lonvo-z.

Intellia Therapeutics (NTLA) Down 7.9% Since Last Earnings Report: Can It Rebound?

Intellia Therapeutics (NTLA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

ADMA vs Intellia Therapeutics: Which Biotech Stock Is a Better Pick Now? 

NTLA gains momentum after positive phase III data for its CRISPR therapy, while ADMA faces pricing and inventory pressure in IG markets. 

Can Intellia's Pipeline Push Drive Long-Term Growth Amid Rivalry?

NTLA advances late-stage studies for nex-z and starts FDA filing for lonvo-z, positioning its pipeline for potential long-term growth.

NTLA Q1 Earnings Beat Estimates, Revenues Miss Mark, Pipeline in Focus

Intellia cuts its Q1 loss, advances late-stage gene-editing programs and plans a 2027 launch for lonvo-z after strong phase III HAE data.

Intellia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Bearish Sentiment

$UBER only

$INTC only

Both $UBER and $INTC

Neither

Nancy Pelosi recently disclosed trades in both Uber ($UBER) and Intel ($INTC) - are you following her into either? Cast your vote below.

Are you following Nancy Pelosi into her latest trades - Uber ($UBER) and Intel ($INTC)?

Current Price	$15.50
Prev Close	$15.25
Open	$15.33
Dividend Yield	0.00%
50-Day Moving Average	$13.86
Beta	1.79
Avg. Volume	6.17M
PE Ratio	-4.39

52-Week High	$28.25
52-Week Low	$7.95
Market Capitalization	$2.13B
EPS (Annual)	-$3.81
Price to Book	3.01
Revenue Per Employee	$179,498.67

Feed

News

Sentiment

Earnings

Fundamentals

Info

NTLAIntellia Therapeutics Inc

Latest NTLA News